We’ve won the People’s Choice at CPhI 2020
October 14, 2020
MedPharm has been named the People’s Choice winner in the Excellence in Pharma: ‘Innovation in Response to COVID-19’ category at the prestigious CPhI Pharma Awards 2020. These annual awards provide recognition to those leading experts in the pharmaceutical industry who turn inspiration into innovation.
MedPharm’s nomination comes as a direct result of our efforts in pioneering and refining new approaches for the development of new cost-effective in vitro models for nasal and lung epithelial tissue. Additionally, in response to the pandemic, MedPharm tailored its unique model to allow companies to assess therapeutic effectiveness of candidates against members of the Coronaviridae family.
Eugene Ciolfi, President and CEO of MedPharm, commented: “To be named as the People’s Choice in this category alongside such big names in the industry is a testament not only to MedPharm’s drive to develop unique new models, but also recognition for quickly adapting to be of immediate assistance to drug developers in the fight against COVID-19. By reducing the risks during drug development, the models are helping speed up development times and ensuring that patients that urgently need treatments, for what can be life threatening conditions, can gain access to effective drugs earlier than might otherwise have been possible.
This award was voted for by the attendees at the annual CPhI Pharma awards which were broadcast live to registrants at CPhI Festival of Pharma globally.
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.